DX&VX Acquires Korea Biopharm for 15 Billion KRW... Secures GMP Production Base

The first factory of Korea Biopharm acquired by DX&VX.

[Asia Economy Reporter Lee Gwan-joo] Dx&Vx announced on the 16th that it acquired 100% of the shares of Korea Bio Pharm, a health functional food company, for 15 billion KRW.

Founded in 1995, Korea Bio Pharm is a specialized manufacturer of health functional foods producing over 120 products in OEM and ODM formats. It operates 10 production lines across its first and second factories, with its main formulation, powder sticks, capable of producing 4.5 billion units annually. Last year, its sales amounted to 13.5 billion KRW, with an operating profit of 1.5 billion KRW.

Through this acquisition, Dx&Vx plans to enter the bio healthcare contract development and manufacturing organization (CDMO) market and establish an integrated business structure encompassing research and development, production, and distribution. Utilizing the acquired in-house GMP production facilities, the company intends to expand exports of bio healthcare products to China starting next month and commercialize technologies and items developed by its microbiome research institute step-by-step, launching about 10 products domestically as well.

Park Sang-tae, CEO of Dx&Vx, stated, “Securing this production base establishes a business structure that connects R&D capabilities to production,” adding, “We will create various products that allow consumers to experience future bio technologies in their daily lives, along with securing new pipelines.”

This content was produced with the assistance of AI translation services.